- Impact Factor of 3.302
- Published at SAGE since 2017
- Article Processing Charge of $2400 USD
- Focus on prevention, detection, diagnosis, treatment, and palliative care of cancer
- Fast and double-blind peer review by dedicated Associate Editors and Editorial Board Members
Cancer Control is a JCR-ranked, peer-reviewed open access journal whose mission is to advance the prevention, detection, diagnosis, treatment, and palliative care of cancer by enabling researchers, doctors, policymakers, and other healthcare professionals to freely share research along the cancer control continuum. Please see the Aims and Scope tab for further information.
This journal is published in association with Moffitt Cancer Center and is a member of the Committee on Publication Ethics (COPE).
Submit your manuscript at https://mc.manuscriptcentral.com/ccx.
Please see the Submission Guidelines tab for more information on how to submit your article to the journal.
Open access article processing charge (APC) information
Publication in the journal is subject to payment of an article processing charge (APC). The APC serves to support the journal and ensures that articles are freely accessible online in perpetuity under a Creative Commons license.
The APC for this journal is currently 2400 USD.
The article processing charge (APC) is payable when a manuscript is accepted after peer review, before it is published. The APC is subject to taxes where applicable. Please see further details here.
Please direct any queries to email@example.com.
Cancer Control is a JCR-ranked open access journal whose mission is to advance the prevention, detection, diagnosis, treatment, and palliative care of cancer by enabling researchers, doctors, policymakers, and other healthcare professionals to freely share research along the cancer control continuum. Our vision is a world where gold-standard cancer care is the norm, not the exception.
The journal is organized into five topical sections, as well as a sixth curated by members of the Moffitt Cancer Center. The topical sections are inspired by the foci of the cancer control continuum (prevention, detection, diagnosis, treatment, survivorship).
Article Types and Topics of Interest
Cancer Control welcomes original research (clinical studies), reviews, and commentaries. We encourage submissions relating to advances in the following areas:
- Communications in cancer research
- Social Determinants of Health Disparities
- Genetic Testing
- Dissemination of Evidence-Based Interventions
- Health Care Delivery and Quality of Care
View a selection of the latest papers published in Cancer Control.
|Applonia Rose, PhD||SAGE Publishing, Thousand Oaks, CA USA|
|Jennifer K. Lovick, PhD||SAGE Publishing, Thousand Oaks, CA USA|
|Priyanka Katyal, PhD||SAGE Publications, New Delhi, India|
|Pooja Sharma, MTech||SAGE Publications, Dehradun, India|
|Jake Bobbe, MA||SAGE Publications Ltd, UK|
|Nirmala Bhoo Pathy, MD, PhD||University of Malaya, Kuala Lumpur, Malaysia|
|Jonathan S. Zager, MD||Moffitt Cancer Center, USA|
|Muhammad N. Aslam, MBBS, MD||University of Michigan, Ann Arbor, USA|
|Muni Balakrishnan Rubens, MD, PhD||Miami Cancer Institute,USA|
|Fernanda Machado Silva-Rodrigues, RN, PhD||Santa Casa de Sao Paulo School of Medical Sciences (FCMSCSP) - Sao Paulo, Brazil|
|Yingkun Xu, PhD||Chongqing Medical University, China|
|Pietro Giorgio Calò, MD||University of Cagliari, Italy|
|Brian J. Czerniecki, MD, PhD||Moffitt Cancer Center, USA|
|Han-Yu Deng||West Chin Hospital, Sichuan University, China|
|Hanan Goldberg, MD||SUNY Upstate Medical University, USA|
|Yiqun Han, MD||Chinese Academy of Medical Sciences and Peking Union Medical College, China|
|Yong-cheng Hu, MD, PhD||Tianjin Hospital, China|
|Mohammad Yasin Karami, MD||Shiraz University of Medical Sciences, Iran|
|Xiangyi Kong, MD, PhD||Chinese Academy of Medical Sciences and Peking Union Medical College, China|
|Luigi Marano, MD, PhD||University of Siena, Siena, Italy|
|Jie Mei, MD||Nanjing Medical University, China|
|Carlos Eduardo Paiva, MD, PhD||Barretos Cancer Hospital, Brazil|
|Alessandro Rizzo, MD||IRCCS Bari Hospital, Italy|
|Ulrich Ronellenfitsch, MD||University Hospital Halle, Halle, Germany|
|Samer Salah, MD||King Hussein Cancer Center, Amman, Jordan|
|PengMing Sun, PhD||Affiliated Hospital of Fujian Medical University, China|
|Song Xu, MD, PhD||Tianjin Medical University General Hospital, China|
|Mohamed A. Yassin, MD||Qatar University, Qatar|
|Nashwa El-Khazragy, MD||Ain Shams University, Cairo, Egypt|
|Abhishek Tyagi, PhD||Wake Forest Baptist School of Medicine, USA|
|Bernard Kwabi-Addo, PhD||Howard University College of Medicine, USA|
|Shengwen Calvin Li, PhD, M.Phil., FRSM, FRSB||CHOC Children's Hospital and University of California, Irvine, USA|
|Haitao Wang, PhD||Center for Cancer Research, NCI, Bethesda, USA|
|Jian-Guo Zhou, MD||The Second Affiliated Hospital of Zunyi Medical University, Zunyi, China|
|Gulzhanat Aimagambetova, MD, PhD||Nazarbayev University, Kazakhstan|
|Massimiliano Bassi, MD||Sapienza University of Rome, Italy|
|Maria Rita Bianco, MD||Magna Graecia University of Catanzaro, Italy|
|Jessica Calderon-Mora, DrPh||Texas Tech University Health Sciences Center El Paso, USA|
|Alejandro Zentella Dehesa, PhD, IIBO-UNAM||National Autonomous University of Mexico, Mexico|
|Durgesh K. Dwivedi, PhD||King George Medical University, India|
|Aydin Eresen, PhD||University of California Irvine, USA|
|Amit Gupta, MS, MBA, FRCS, FACS||All India Institute of Medical Sciences, India|
|Ferda Kaleagasioglu, MD||Istinye University, Turkey|
|Sk. Kayum Alam, PhD||University of Minnesota, USA|
|Mohammad Amin Kerachian, MD, PhD, RMF||Mashhad University of Medical Sciences, Iran|
|Divya Khanna, MBBS, MD, PDCR||TATA Memorial Cancer Center|
|Jew Win Kuan, MBBS, MRCP, PhD||Universiti Malaysia Sarawak, Malaysia|
|Chan-Yen Kuo, PhD||Taipei Tzuchi Hospital, Taiwan|
|Enoch Luis, PhD||Instituto de Fisiología Celular, Mexico|
|Ankit Madan, MD||SOVAH Cancer Centre|
|Kate A. McBride, MPH, Grad Cert, PhD||Western Sydney University, Australia|
|Mona Osman, MD, MPH, MBA, Dipl IBLM||American University of Beirut, Lebanon|
|See-Hyoung Park, PhD||Hongik University, Republic of Korea|
|Alexandros Poutoglidis, MD,MSc,PhD(c),FEB(ORL-HNS)||Genera Hospital of Thessaloniki, Greece|
|Xianon Shao, MD, PhD||The Third Affiliated Hospital of Soochow University, China|
|Jie Shen, PhD, MS||Massey Cancer Center, USA|
|Micah A. Skeens, PhD, RN, APRN||Abigail Research Institute at Nationwide Children’s Hospital, USA|
|Sumsum P. Sunny, MDS, MSc||Mazumdar Shaw Cancer Center, India|
|Ovidiu Tatar, MD, MSc||Lady Davis Institute for Medical Research, Canada|
|Clifton P. Thornton, PhD, RN, CPNP||John Hopkins University, USA|
|Georgios Tsoulfas, MD, PhD, FACS||Aristotle University School of Medicine, Greece|
|I-Shiang Tzeng, MBA, PhD||Taipei Tzuchi Hospital, Taiwan|
|Alessandro Uleri, PhD||Humanitas University, Italy|
|Che Hsueh Yang, MD||Tungs' Taichung MetroHarbor Hospital, Taiwan|
|Zhihao Yang, PhD||Tianjin University, China|
|Zhiwen Yang, PhD||Songjiang Hospital Affiliated to the First People´s Hospital of Shanghai Jiaotong University, China|
|Andee Dzulkarnaen Zakaria, MD, M.Med||Universiti Sains Malaysia, Malaysia|
|Chunzhi Zhang, PhD, MM, MB||Tianjin Hospital, China|
|Matthew Allsop, PhD||University of Leeds, UK|
|Daniel A. Anaya, MD||Moffitt Cancer Center, USA|
|Aliyah Baluch, MD||Moffitt Cancer Center, USA|
|Idriss M. Bennani-Baiti, PhD, FRSM, CRSM||Cancer Epigenetics Society, Austria|
|Dung-Tsa Chen, PhD||Moffitt Cancer Center, USA|
|Hye Sook Chon, MD||Moffitt Cancer Center, USA|
|Michele L. Cote, PhD, MPH||Wayne State University, USA|
|Mahmoud Danaee, PhD||University of Malaya, Kuala Lumpur, Malaysia|
|Jasreman Dhillon, MD||Moffitt Cancer Center, USA|
|Ilana F. Gareen, PhD||Brown University, USA|
|Clement K. Gwede, PhD, RN||Moffitt Cancer Center, USA|
|Sarah E. Hoffe, MD||Moffitt Cancer Center, USA|
|Jagdish Khubchandani, MBBS, PhD||New Mexico State University, USA|
|John V. Kiluk, MD||Moffitt Cancer Center, USA|
|Kyuwoong Kim, PhD||National Cancer Control Institute, National Cancer Center, Republic of Korea|
|Richard D. Kim, MD||Moffitt Cancer Center, USA|
|Bela Kis, MD, PhD||Moffitt Cancer Center, USA|
|Rami Komrokji, MD||Moffitt Cancer Center, USA|
|Marilyn L. Kwan, PhD||Kaiser Permanente Northern California - Division of Research, USA|
|Conor C. Lynch, PhD||Moffitt Cancer Center, USA|
|Catherine M. Olsen||QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia|
|Kristen J. Otto, MD||Moffitt Cancer Center, USA|
|Michael A. Poch, MD||Moffitt Cancer Center, USA|
|Elizabeth M. Sagatys, MD||Moffitt Cancer Center, USA|
|Saïd M. Sebti, PhD||Moffitt Cancer Center, USA|
|Bijal D. Shah, MD||Moffitt Cancer Center, USA|
|Lubomir Sokol, MD, PhD||Moffitt Cancer Center, USA|
|Hatem H. Soliman, MD||Moffitt Cancer Center, USA|
|Jonathan R. Strosberg, MD||Moffitt Cancer Center, USA|
|Jennifer Swank, PharmD||Moffitt Cancer Center, USA|
|Sarah W. Thirlwell, MSc, MSc(A), RN||Moffitt Cancer Center, USA|
|Jasmine A. Tiro, PhD||University of Texas Southwestern Medical Center, USA|
|Eric M. Toloza, MD, PhD||Moffitt Cancer Center, USA|
|Nam D. Tran, MD||Moffitt Cancer Center, USA|
|Yi Zhang, MD, PhD||The First Affiliated Hospital of Zhengzhou University, China|
Before you submit your research, please make sure your paper meets the below criteria:
Your paper is an original work and has not been published or currently under review with another journal.
Only authors that have contributed to the work are added. Please see ICMJE's guidelines "Defining Roles of Authors and Contributors".
Your work meets all Research Ethics and Reporting Standards. Many study types require a workflow as a figure and/or a completed checklist uploaded as a supplementary file for peer review. Visit here to see if your study type requires a workflow and/or checklist.
Your figures are of acceptable quality and uploaded as separate files. Line art should be 900-1200 DPI, images 300 DPI. Images should be minimally processed to uphold their original integrity. More figure information here.
Your references are formatted correctly and numbered as they appear in the text. Please visit here for reference style.
Data and complete methods should be made available so that others may replicate your study. If applicable, please see here for more information and data repositories.
Authors must have an understanding and agreement to pay any applicable article processing charges (APCs).
Only manuscripts of sufficient quality that meet the aims & scope of the journal will be reviewed.
Full guidelines are below. Submissions that don't adhere to these instructions will be returned prior to peer review.
Once your manuscript meets all criteria above and below, you can submit it through our online submission system here.
This Journal is a member of the Committee on Publication Ethics.
This Journal recommends that authors follow the Recommendations for the Conduct, Reporting, Editing,
and Publication of Scholarly Work in Medical Journals formulated by the International Committee of
Medical Journal Editors (ICMJE).
Please read the guidelines below then visit the journal’s submission site
http//mc.manuscriptcentral.com/ccx to upload your manuscript. Please note that manuscripts not
conforming to these guidelines may be returned. Remember you can log in to the submission site at any time to check on the progress of your paper through the peer review process.
SAGE Publishing dissseminates high-quality research and engaged scholarship globally, and we are committed to dirversity and inclusion in publishing. We encourage submissions from a diverse range of authors from across all countries and backgrounds.
Only manuscripts of sufficient quality that meet the aims and scope of Cancer Control will be reviewed.
As part of the submission process, you will be required to warrant that you are submitting your original
work, that you have the rights in the work, that you are submitting the work for first publication in the
Journal and that it is not being considered for publication elsewhere and has not already been published
elsewhere, and that you have obtained and can supply all necessary permissions for the reproduction of
any copyright works not owned by you.
If you have any questions about publishing with SAGE, please visit the SAGE Journal Solutions Portal
Please read the Manuscript Submission Guidelines below before submitting your manuscript here:
- Open Access
- Article processing charge (APC)
- What do we publish?
3.1 Aims & scope
3.2 Article types
3.3 Writing your paper
3.3.1 Making your article discoverable
- Editorial policies
4.1 Peer Review Policy
4.5 Declaration of conflicting interests
4.6 Research ethics and patient consent
4.7 Clinical Trials
4.8 Reporting guidelines
4.9 Research data
- Publishing policies
5.1 Publication ethics
5.2 Contributor's publishing agreement
- Preparing your manuscript
6.1 Word processing formats
6.1.1 Title and Authors (On a separate title page)
6.1.2 Manuscript Preparation
6.2 Artwork, figures and other graphics
6.3 Supplementary material
6.4 Reference style
6.5 English language editing services
- Submitting your manuscript
7.1 How to submit your manuscript
7.2 Title, keywords and abstracts
7.3 Information required for completing your submission
7.5 Information required for completing your submission
- On acceptance and publication
8.1 SAGE Production
8.2 Continuous publication
8.3 Promoting your article
- Further information
Cancer Control is an open access, peer-reviewed journal. Each article accepted by peer review is made
freely available online immediately upon publication is published under a Creative Commons license
and will be hosted online in perpetuity. Publication costs of the journal are covered by the collection of
article processing charges which are paid by the funder, institution or author of each manuscript upon
acceptance. There is no charge for submitting a paper to the journal.
If, after peer review, your manuscript is accepted for publication, a one-time article processing charge (APC) is payable. This APC covers the cost of publication and ensures that your article will be freely available online in perpetuity under a Creative Commons license.
The article processing charge (APC) for this journal is currently 2400 USD, payable only if your article is accepted after peer review, before it is published.
The APC is subject to taxes where applicable. Tax-exempt status can be indicated by providing appropriate registration numbers when payment is requested. Please see further details here.
Before submitting your manuscript to Cancer Control, please ensure you have read the Aims & Scope.
For studies that only contain bioinformatics, computational analysis, or predictions made using public databases, the journal only considers those manuscripts which include robust external validation using an independent cohort or biological validation in vitro or in vivo and have potential clinical applications.
At the time of submission, authors are required to answer three questions, which will be
incorporated into a “highlights” section at the beginning of the published article.
- What do we already know about this topic?
- How does your research contribute to the Cancer Control field?
- What are your research’s implications towards theory, practice, or policy
Original Research Papers
While there are no strict formatting requirements all manuscripts must still contain abstract,
introduction, materials and methods, results, and discussion/conclusion sections.
Please make sure the abstract is a structured abstract with fewer than 250 words. The primary goal of the
abstract should be to make the general significance and conceptual advance of the work clearly
accessible to a broad readership. References should not be cited in the abstract. Refer to this guide for properly structuring abstracts.
We also ask that you provide 5-10 keywords for indexing purposes.
In the Materials & Methods section, describe the selection of patients or experimental animals,
including controls. Do not use patient’s names or hospital numbers. Identify methods, apparatus
(manufacturer’s name and address), and procedures in sufficient detail to allow other workers
to reproduce the results. Provide references and brief descriptions of methods that have been
published. When using new methods, evaluate their advantages and limitations. Identify drugs
and chemicals, including generic name, dosage, and route(s) of administration.
Results should be presented in a logical sequence in tables and illustrations. In the text, explain,
emphasize or summarize the most important observations. Units of measurement should be
expressed in accordance with Systeme International Unites (SI Units).
In the discussion do not repeat in detail data given in the Results section. Emphasize the new
and important aspects of the study. Relate observations to other relevant studies. On the basis
of your findings (and others), discuss possible implications/conclusions. When stating a new
hypothesis, clearly label it as such.
There is no limit for references.
Tables should be numbered consecutively with Arabic numerals and include descriptive titles
Figure legends should be concise, yet descriptive so that the reader can clearly interpret the
results being presented.
These are short experimental papers that may present as little as a single experiment or
observation. Brief Reports should constitute unusually interesting data combined with a
discussion of what the data might mean, or an explanation of why the data contradicts current
The abstract includes a single paragraph of fewer than 150 words. The primary goal of the abstract
should be to make the general significance and conceptual advance of the work clearly
accessible to a broad readership. Please include 5-10 keywords for indexing purposes.
Reviews should be recognized as scholarly by specialists in the covered field, but should
also be written with a view to informing readers who are not specialized in that particular field,
and should be presented using simple prose. Please avoid excessive jargon and
technical detail. Reviews should capture the broad developments and implications of recent
work. The opening paragraph should make clear the general thrust of the review and provide a
clear sense of why the review is now particularly appropriate. The concluding paragraph should
provide the reader with an idea of how the field may develop or future problems to be
overcome, but should not summarize the article. To ensure that a review is likely to be
accessible to as many readers as possible, it may be useful to ask a colleague from another
discipline to read the review before submitting it. Submitted reviews are subject to the same
charges as original papers -- whether APCs will apply for commissioned reviews will be made
clear when each review is commissioned. Reviews should include an abstract of 150 words and
should cite no more than 150 references. Please include 5-10 keywords for indexing purposes.
Mini Reviews are articles that focus on recent significant advances in fields that are within the scope of Cancer Control. They are clear, succint summaries that provide an up-to-date overview of progress, new developments, and/or emerging concepts in a specific field. Mini Reviews must provide clinical context and discussion of challenges and potential future developments. Mini Reviews should be approximately 2000 words. The abstract should not exceed 350 words and should be structured with a background, main body, and short conclusion. Mini Reviews should not include unpublished material or personal communications.
Study Protocols are articles that describe the design of planned or ongoing research. This includes study design for observational, qualitative, exploratory studies, experimental studies, and systematic reviews. Study designs for clinical trials are especially encouraged. Cancer Control endorses the SPIRIT (Standard Protocol Items: Recommendations for Interventional Trials) Statement, which provides important guidance on drafting protocols, and the PRISMA-P (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines, which provide a 17-item checklist for preparing systematic review and meta-analysis protocols. Authors are encouraged to follow these guidelines when preparing a study protocol manuscript. For more information on preparing a Study Protocol for submission, refer to this document.
The Editor or Editorial Board will solicit authors of the most significant recent and forthcoming
papers, published elsewhere, to provide a short summary with additional insights, new
interpretations or speculation on the relevant topic. These manuscripts may include data or
models, which due to space limitations were not included or discussed in the original paper. In
other words, the authors may provide biased and uncensored points of views, complementing
Please include an abstract of 150-200 words and 5-10 keywords for indexing purposes. The
citation for the original article including the full author list, title of article and journal
information should be included on the title page. The typical length of an auto-commentary will
be approximately 500-1,000 words and may include up to 30 references.
Commentaries and Views
Commentaries and/or views may be short and focused opinion articles, commentaries on
papers recently published in Cancer Control or elsewhere, or commentaries on significant
conceptual changes, important trends or new directions in the field. These may include figures
and up to 30 references. Please include an abstract of 150-200 words and 5-10 keywords for
Journal Club articles to include descriptions and critiques of major advances published in other
leading journals. This will be modeled after and driven by journal club presentations held in
most institutions around the country.
Technical papers contain original research, however, they differ from Research Papers in that
they describe new approaches, methods, or reagents rather than new understanding of a
natural molecule or biological process. Papers may be submitted as either Technical or
Research Papers, but the assignment to either category is the discretion of the Editors. All
submissions will be peer reviewed.
Letters to the Editor
Letters to the Editor should consist of one or two paragraphs totaling no more than 500 words,
no abstract, no subheadings and fewer than 8 references (one author, et al., no titles). If an
abstract is included, it will automatically be made the first paragraph. Letters should not include
figures or research material. Letters to the editor are not charged an APC.
A letter to the editor is a brief communication that addresses the contents of a published article.
Its purpose is to make corrections, provide alternative viewpoints, or offer counter-arguments. Avoid
logical fallacies and ad hominem attacks. Letters to the editor must be written in a professional tone
and include references to support all claims if appropriate.
Validation or Replication studies can be submitted to the journal. These should be carried out to validate that a scientific finding is accurate, reliable and reproducible. These may be written in the style of a Brief Communication or a Research Paper with a brief introduction.
The SAGE Author Gateway has some general advice and on how to get published, plus links to further resources.
When writing up your paper, think about how you can make it discoverable. The title, keywords and abstract are key to ensuring readers find your article through search engines such as Google. For information and guidance on how best to title your article, write your abstract and select your keywords, have a look at this page on the Gateway: How to Help Readers Find Your Article Online.
Cancer Control offers transparent peer review as a choice for authors, where the reviews at each stage, author responses and editor’s decision letters will be publicly available on Publons and linked to from the published article should the article be accepted. Authors have the opportunity to opt-out during submission. Reviewers are encouraged to sign their reviews but their comments will be published anonymously should they choose not to do so.
Following a preliminary triage to eliminate submissions unsuitable for Cancer Control all papers are sent out for review. The covering letter is important. To help the Editor in his preliminary evaluation, please indicate why you think the paper is suitable for publication.
The journal’s policy is to have manuscripts reviewed by two expert reviewers. Cancer Control utilizes a double-anonymize peer review process in which the reviewer and authors’ names and information are withheld from the other. All manuscripts are reviewed as rapidly as possible while maintaining rigor. Reviewers make comments to the author and recommendations to the Section Editor and Editor-in-Chief who then makes the final decision.
The Editor or members of the Editorial Board may occasionally submit their own manuscripts for
possible publication in the journal. In these cases, the peer review process will be managed by
alternative members of the Board and the submitting Editor / Board member will have no
involvement in the decision-making process.
Papers should only be submitted for consideration once consent is given by all contributing
authors. Those submitting papers should carefully check that all those whose work contributed
to the paper are acknowledged as contributing authors.
The list of authors should include all those who can legitimately claim authorship. This is all
(i) Made a substantial contribution to the concept or design of the work; or acquisition,
analysis or interpretation of data,
(ii) Drafted the article or revised it critically for important intellectual content,
(iii) Approved the version to be published,
(iv) Each author should have participated sufficiently in the work to take public
responsibility for appropriate portions of the content.
Authors should meet the conditions of all of the points above. Each author should have
participated sufficiently in the work to take public responsibility for appropriate portions of the
When a large, multicentre group has conducted the work, the group should identify the
individuals who accept direct responsibility for the manuscript. These individuals should fully
meet the criteria for authorship.
Acquisition of funding, collection of data, or general supervision of the research group alone
does not constitute authorship, although all contributors who do not meet the criteria for
authorship should be listed in the Acknowledgments section. Please refer to the International
Committee of Medical Journal Editors (ICMJE) authorship guidelines for more information on
All contributors who do not meet the criteria for authorship should be listed in an Acknowledgements section. Examples of those who might be acknowledged include a person who provided purely technical help, or a department chair who provided only general support.
4.3.1 Third party submissions
Where an individual who is not listed as an author submits a manuscript on behalf of the author(s), a statement must be included in the Acknowledgements section of the manuscript and in the accompanying cover letter. The statements must:
• Disclose this type of editorial assistance – including the individual’s name, company and level of input
• Identify any entities that paid for this assistance
• Confirm that the listed authors have authorized the submission of their manuscript via third party and approved any statements or declarations, e.g. conflicting interests, funding, etc.
Where appropriate, SAGE reserves the right to deny consideration to manuscripts submitted by a third party rather than by the authors themselves.
4.3.2 Writing assistance
Individuals who provided writing assistance, e.g. from a specialist communications company, do not qualify as authors and so should be included in the Acknowledgements section. Authors must disclose any writing assistance – including the individual’s name, company and level of input – and identify the entity that paid for this assistance. It is not necessary to disclose use of language polishing services. Please supply any personal acknowledgments separately to the main text to facilitate anonymous peer review.
Cancer Control requires all authors to acknowledge their funding in a consistent fashion under a separate heading. Please visit the Funding Acknowledgements page on the SAGE Journal Author Gateway to confirm the format of the acknowledgment text in the event of funding, or state that: This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
It is the policy of Cancer Control to require a declaration of conflicting interests from all authors enabling a statement to be carried within the paginated pages of all published articles. Please ensure that a ‘Declaration of Conflicting Interests’ statement is included at the end of your manuscript, after any acknowledgments and prior to the references. If no conflict exists, please state that ‘The Author(s) declare(s) that there is no conflict of interest’.
For guidance on conflict of interest statements, please see the ICMJE recommendations.
IMPORTANT: If you are reporting on animal and/or human studies, please ensure that you
include a section on research ethics and, where applicable, patient consent, at the end of your
Medical research involving human subjects must be conducted according to the World Medical
Association Declaration of Helsinki.
Submitted manuscripts should conform to the ICMJE Recommendations for the Conduct,
Reporting, Editing, and Publication of Scholarly Work in Medical Journals, and all papers
reporting animal and/or human studies must state the relevant Ethics Committee or
Institutional Review Board provided (or waived) approval. Please ensure that you have provided
the full name and institution of the review committee, in addition to the approval number.
For research articles, authors are also required to state whether participants provided informed
consent and whether the consent was written or verbal.
Information on informed consent to report individual cases or case series should be included in the
manuscript text. A statement is required regarding whether written informed consent for patient
information and images to be published was provided by the patient(s) or a legally authorized
representative. Please do not submit the patient’s actual written informed consent with your article,
as this in itself breaches the patient’s confidentiality. The Journal requests that you confirm to us, in
writing, that you have obtained written informed consent but the written consent itself should be held
by the authors/investigators themselves, for example in a patient’s hospital record. The confirmatory
letter may be uploaded with your submission as a separate file.
Please also refer to the ICMJE Recommendations for the Protection of Research Participants
All research involving animals submitted for publication must be approved by an ethics committee with oversight of the facility in which the studies were conducted. The Journal has adopted the ARRIVE guidelines.
Cancer Control conforms to the ICMJE requirement that clinical trials are registered in a WHO-approved public trials registry at or before the time of first patient enrolment as a condition of consideration for publication. The trial registry name and URL, and registration number must be included at the end of the abstract.
The relevant EQUATOR Network reporting guidelines should be followed depending on the type
of study. For example, all randomized controlled trials submitted for publication should include
a completed CONSORT flow chart as a cited figure and the completed CONSORT checklist should
be uploaded with your submission as a supplementary file. Systematic reviews and meta-analyses
should include the completed PRISMA flow chart as a cited figure and the completed
PRISMA checklist should be uploaded with your submission as a supplementary file. For observational studies in epidemiology (cohort, case-control, cross-sectional studies) the completed STROBE checklist should be uploaded with your submission as a supplementary file. The
EQUATOR wizard can help you identify the appropriate guideline.
Other resources can be found at NLM’s Research Reporting Guidelines and Initiatives.
The journal is committed to facilitating openness, transparency and reproducibility of research, and has the following research data sharing policy. For more information, including FAQs please visit the SAGE Research Data policy pages.
Subject to appropriate ethical and legal considerations, authors are encouraged to:
- share your research data in a relevant public data repository
- include a data availability statement linking to your data. If it is not possible to share your data, we encourage you to consider using the statement to explain why it cannot be shared.
- cite this data in your research
SAGE is committed to upholding the integrity of the academic record. We encourage authors to
refer to the Committee on Publication Ethics’ International Standards for Authors and view the
Publication Ethics page on the SAGE Author Gateway.
Cancer Control and SAGE take issues of copyright infringement, plagiarism or other breaches of best practice in publication very seriously. We seek to protect the rights of our authors and we always investigate claims of plagiarism or misuse of published articles. Equally, we seek to protect the reputation of the journal against malpractice. Submitted articles may be checked with duplication-checking software. Where an article, for example, is found to have plagiarized other work or included third-party copyright material without permission or with insufficient acknowledgment, or where the authorship of the article is contested, we reserve the right to take action including, but not limited to: publishing an erratum or corrigendum (correction); retracting the article; taking up the matter with the head of department or dean of the author's institution and/or relevant academic bodies or societies; or taking appropriate legal action.
5.1.2 Prior publication
If any material has been previously published, it is not generally acceptable for publication in a SAGE journal. However, there are certain circumstances where previously published material can be considered for publication. Please refer to the guidance on the SAGE Author Gateway or if in doubt, contact the Editor at the address given below.
Before publication SAGE requires the author as the rights holder to sign a Journal Contributor’s
Publishing Agreement. Cancer Control publishes manuscripts under Creative Commons licenses.
The standard license for the journal is Creative Commons by Attribution Non-Commercial (CC
BY-NC), which allows others to re-use the work without permission as long as the work is
properly referenced and the use is non-commercial. For more information, you are advised to
visit SAGE's OA licenses page.
Alternative license arrangements are available, for example, to meet particular funder
mandates, made at the author’s request.
The preferred format for your manuscript is Word. LaTeX files are also accepted. Word and (La)Tex templates are available on the Manuscript Submission Guidelines page of our Author Gateway.
- The title should be in upper and lower case (Do not use all UPPERcase)
- Author first name (or initials), middle initial, and last name (surname, family name)
- and degree(s)
- Affiliations: use 1, 2, etc. after the degree
- Put an * after the name of the corresponding author
The abstract should be 250-300 words and should reflect the results. Describe the
purpose of the study and briefly explain how the study was performed. Summarize the
most important observations and their significance. Do not use abbreviations in the
Following the abstract, please list 5-6 keywords for indexing the article. Keywords, along
with the abstract and title, are central to ensuring that readers can search for and find
your article online. For this reason, to aid in search-ability, words in the title should not
be used as keywords. For keyword suggestions, please visit the National Library of
Medicine’s Medical Subject Headings (MeSH®) website.
Please include a list of all abbreviations used in the manuscript. These should be listed
in alphabetical order. (Example: MRI, Magnetic Resonance Imaging; RT, Radiation
Provide background that allows readers outside the discipline to understand the significance
of the study. Include a brief review of important literature in the relevant field.
References cited should be in parentheses ( ).
Materials and Methods
Please do not use numbering or subheadings. Describe in detail any new methods or
protocols used, in order that other investigators can replicate the study. Older, better known
methods may be cited in references but should be described enough that the
reader may understand the method.
Specific Reporting Guidelines
Medical research involving human subjects must be conducted according to the World
Medical Association Declaration of Helsinki. Submitted manuscripts should conform to
the ICMJE Recommendations for the Conduct, Reporting, Editing, and Publication of
Scholarly Work in Medical Journals, and all papers reporting animal and/or human
studies must state in the methods section that the relevant Ethics Committee or
Institutional Review Board provided (or waived) approval. Please ensure that you have
provided the full name and institution of the review committee, in addition to the
approval number. For research articles, authors are also required to state in the
methods section whether participants provided informed consent and whether the
consent was written or verbal.
Human Subject Research
If using human subjects, the methods section must include ethics statements that
- The name of the approving institutional review board (IRB) or equivalent
committees. If approval was not obtained, a detailed statement
explaining the reason is required.
- Nature of Informed consent – oral or written. If oral, how the consent
was documented should be stated in the manuscript. If written consent
was not obtained, the reasons should be stated in the manuscript.
The methods section of the manuscript reporting animal research must include
ethics statements that specify the relevant ethics committee approving the
research, and associate permit number(s). If ethical approval was not required,
reasons should be stated in the manuscript. Relevant details to minimize
suffering of the animal should be mentioned.
Cell Line Research
The methods section should state the origin of the cell lines. In cases of established
cell lines, in addition to origin, the commercial source should be given. If
previously unpublished new cell lines were used, the source should be
Explain how the results relate to the premise of the study especially in relation to
previous related studies and how the present study results might have potential in
directing future research.
Describe the interpretation of the data.
Avoid overemphasizing the conclusion.
Conflict of Interests Statement
At the end of the manuscript, before the Acknowledgements section, statements
related to conflicts of interest must appear.
List the names of the individuals along with the contributors who have participated in
some capacity but cannot be qualified as authors.
Disclose if any funds were received to conduct the research.
Cancer Control adheres to AMA reference style. In the references section
(i.e., bibliography), please list references in the same order as they were cited
in the manuscript. When a website is cited as a reference, provide the date that
the website was last accessed.
Unpublished data and personal correspondence may be cited as references within the
text itself and are not to be included in the list of references. Authors are fully
responsible for the accuracy of references used, and all text quoted. Manuscripts
submitted in any other format may delay the publication of your article.
For guidance on the preparation of illustrations, pictures and graphs in electronic format, please visit SAGE’s Manuscript Submission Guidelines
Figures supplied in color will appear in color online.
This journal is able to host additional materials online (e.g. datasets, podcasts, videos, images etc.) alongside the full-text of the article. For more information please refer to our guidelines on submitting supplemental files.
Authors seeking assistance with English language editing, translation, or figure and manuscript formatting to fit the journal’s specifications should consider using SAGE Language Services. Visit SAGE Language Services on our Journal Author Gateway for further information.
Cancer Control is hosted on SAGE Track, a web-based online submission and peer review system powered by ScholarOne™ Manuscripts. Visit here to login and submit your article online.
IMPORTANT: Please check whether you already have an account in the system before trying to create a new one. If you have reviewed or authored for the journal in the past year it is likely that you will have had an account created. For further guidance on submitting your manuscript online please visit ScholarOne Online Help.
Please supply a title, short title, an abstract and keywords to accompany your article. The title, keywords and abstract are key to ensuring readers find your article online through online search engines such as Google. Please refer to the information and guidance on how best to title your article, write your abstract and select your keywords by visiting the SAGE Journal Author Gateway for guidelines on How to Help Readers Find Your Article Online.
Provide full contact details for the corresponding author including email, mailing address and telephone numbers. Academic affiliations are required for all co-authors. These details should be presented separately to the main text of the article to facilitate anonymous peer review. You will be asked to provide contact details and academic affiliations for all co-authors via the submission system and identify who is to be the corresponding author. These details must match what appears on your manuscript. At this stage please ensure you have included all the required statements and declarations and uploaded any additional supplementary files (including reporting guidelines where relevant).
As part of our commitment to ensuring an ethical, transparent and fair peer review process SAGE is a
supporting member of ORCID, the Open Researcher and Contributor ID. ORCID provides a unique
and persistent digital identifier that distinguishes researchers from every other researcher, even
those who share the same name, and, through integration in key research workflows such as
manuscript and grant submission supports automated linkages between researchers and their
professional activities, ensuring that their work is recognized.
The collection of ORCID iDs from corresponding authors is now part of the submission process of this
journal. If you already have an ORCID iD you will be asked to associate that to your submission
during the online submission process. We also strongly encourage all co-authors to link their ORCID
ID to their accounts in our online peer review platforms. It takes seconds to do: click the link when
prompted, sign in to your ORCID account and our systems are automatically updated. Your ORCID iD
will become part of your accepted publication’s metadata, making your work attributable to you and
only you. Your ORCID iD is published with your article so that fellow researchers reading your work
can link to your ORCID profile and from there link to your other publications.
You will be asked to provide contact details and academic affiliations for all co-authors via the
submission system and identify who is to be the corresponding author. These details must match
what appears on your manuscript. The affiliation listed on the manuscript should be the institution
where the research was conducted. If an author has moved to a new institution since completing the
research, the new affiliation can be included in a manuscript note at the end of the paper. At this stage
please ensure you have included all the required statements and declarations and uploaded any
additional supplementary files (including reporting guidelines where relevant).
Authors are responsible for obtaining permission from copyright holders for reproducing any illustrations, tables, figures or lengthy quotations previously published elsewhere. For further information including guidance on fair dealing for criticism and review, please visit our Frequently Asked Questions on the SAGE Journal Author Gateway.
If your paper is accepted for publication after peer review, you will first be asked to complete the contributor’s publishing agreement. Once your manuscript files have been checked for SAGE Production, the corresponding author will be asked to pay the article processing charge (APC) via a payment link. Once the APC has been processed, your article will be prepared for publication and can appear online within an average of 30 days. Please note that no production work will occur on your paper until the APC has been received.
Your SAGE Production Editor will keep you informed as to your article’s progress throughout the production process. Proofs will be made available to the corresponding author via our editing portal SAGE Edit, or by email to the corresponding author and should be returned promptly. Authors are reminded to check their proofs carefully to confirm that all author information, including names, affiliations, sequence and contact details are correct, and that Funding and Conflict of Interest statements, if any, are accurate. Please note that if there are any changes to the author list at this stage all authors will be required to complete and sign a form authorizing the change.
One of the many benefits of publishing your research in an open access journal is the speed to publication. With no page count constraints, your article will be published online in a fully citable form with a DOI number as soon as it has completed the production process. At this time it will be completely free to view and download for all.
Publication is not the end of the process! You can help disseminate your paper and ensure it is as widely read and cited as possible. The SAGE Author Gateway has numerous resources to help you promote your work. Visit the Promote Your Article page on the Gateway for tips and advice.
Any correspondence, queries or additional requests for information on the Manuscript Submission process should be sent to the Cancer Control Editorial Office | firstname.lastname@example.org